Dec 14, 2019
NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC
DRAMMATIC SWOG S1803 NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct...
1,180
Dec 14, 2019
NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM Dara-KPd This research study is studying the...
389
Dec 13, 2019
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM...
201
Dec 13, 2019
NCT04108624: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients Study to Assess for Measurable Residual Disease (MRD)...
318
Dec 13, 2019
NCT03858205: Low-Dose Radiotherapy in Treating Painful Bone Metastases in Multiple Myeloma Patients
NCT03858205: Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma Low-Dose Radiotherapy in...
77
Dec 13, 2019
NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma NKTR-255 in Relapsed/Refractory Multiple...
139
Dec 13, 2019
NCI National Cancer Institute : Randomization in Clinical Trials
NCI National Cancer Institute : Randomization in Clinical Trials
81
Dec 13, 2019
NCT03896737: Phase 2: EMN 18 - Dara-VCd VS VTd Then Maintenance With Ixazomib (IXA) or IXA-Dara
EMN 18 Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib...
222
Dec 13, 2019
24th Congress of the European Hematology Association Amsterdam, The Netherlands - June 13 - 16, 2019
EHA 24th Congress of the European Hematology Association Amsterdam, The Netherlands - June 13 - 16, 2019 Learn more:...
158
Dec 13, 2019
Mass spectrometry | Atomic structure and properties | AP Chemistry | Khan Academy
Mass spectrometry | Atomic structure and properties | AP Chemistry | Khan Academy Mass spectrometry | Atomic structure and properties |...
63
Dec 13, 2019
NCT04000282: Phase 1: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory MM
NCT04000282: Phase 1: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma NCT04000282: Phase 1:...
56
Dec 13, 2019
NCT03915184: Phase 1 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory
(LUMMICAR STUDY 2) NCT03915184: Phase 1 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma...
370
Dec 13, 2019
NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed RRMM
Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5459 NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With...
241
Dec 13, 2019
NCT04091126: Phase 1 - Belantamab Mafodotin + Standard of Care New Multiple Myeloma (DREAMM 9) NDMM
DREAMM 9 - Transplant Ineligible - Newly Diagnosed Multiple Myeloma Part 1: Dose escalation and cohort expansion Part 2: Dose selection...
401
Dec 13, 2019
NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma PD-L1 Peptide Vaccination in High Risk...
67
Dec 12, 2019
NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM
DETER-SMM EAA173 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma...
746
Dec 12, 2019
NCT04123418: Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM)
RRMM NCT04123418: Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM) A Study of WVT078 in Patients With Multiple Myeloma...
121
Dec 12, 2019
NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies - RRMM Myeloma
NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in...
36
Dec 12, 2019
17th International Myeloma Workshop: September 12-15, 2019 Boston, MA
17th International Myeloma Workshop September 12-15, 2019 Boston, MA http://www.imw2019boston.org/ https://www.myelomasociety.org/publica...
150